Therapeutic efficacy and biocompatibility of triamcinolone acetonide-loaded lipid nanocapsules

MARÍA LINA FORMICA; GABRIELA ULLIO GAMBOA; JEAN-PIERRE BENOIT,; DANIEL ALBERTO ALLEMANDI; SANTIAGO DANIEL PALMA

Buenos Aires

Congreso; Reunión conjunta de Sociedades de Biociencias; 2017

SAFE

Triamcinolone acetonide (TA) is a synthetic corticosteroid used to treat a broad spectrum of ocular diseases. The development of TA dosage forms is limited due to its poor solubility in physiologically acceptable solvents. The aim of this work was to evaluate therapeutic efficacy in-vitro of novel ?solvent free? TA-loaded lipid nanocapsules (LNC). An optimized phase inversion temperature method was used to obtain TA-loaded LNC with oleic acid or glyceryl triacetate into lipid matrix. The average particle size (APS), polydispersity index (PI) and loading capacity (LC) of LNC were measured. Cell viability of human corneal epithelial (HCE) cells after TA-loaded LNC exposure was evaluated using MTT assay. In addition, the secretion of the inflammatory cytokine IL-6 by HCE cells in response to tumor necrosis factor (TNF)-α exposure (inflamed cells) was measured after treatment with TA-loaded LNC. Inflamed cells were exposed to TA-loaded LNC for a 1h and IL-6 secreted into the culture medium was measured by ELISA. Obtained TA-loaded LNC showed acceptable APS, PI and LC. Results of biocompatibility assay did not show any significant cytotoxic effect (cell viability>70%) of TA-loaded LNC in HCE cells over studied period. Experimental findings exhibited efficacy of TA-loaded LNC to reduce cell inflammation. IL-6 levels secreted by TNF-α inflamed cells were upper compared to those basally secreted by non-inflamed cells(p≤0,05). Exposition of inflamed cells to TA-loaded LNC (1µg/ml) for the 1h, significantly reduced IL-6 production compared to control inflamed untreated cells(p≤0,05). Empty LNC increase the cell inflammation significantly(p≤0,005) while that TA trademark suspension showed a significant IL-6 secretion decrease(p≤0,05) in comparison to both controls: non-inflamed and inflamed untreated cells. This strategy allowed the decrease of IL-6 level of HCE cells and it could be a potential alternative to treat several ocular diseases with less adverse effects.